Inhixa Multi
Inhixa Multi is a biosimilar from Viatris Pharma GmbH and is listed on the FOPH Specialities List. As the follow-on product of a biologic it is reimbursed by basic health insurance. The public price ranges from CHF 34.45 to CHF 34.45 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Viatris Pharma GmbH
- ATC code
- B01AB05
- IT group
- 06.03.30 Heparin
- Active substances
- Enoxaparinum natricum
- Preparation type
- Biosimilar
- On the SL since
- 01/08/2020
- Last price change
- 01/12/2024
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inj Lös 300 mg/3ml | Durchstf 3 ml | CHF 16.59 | CHF 34.45 | 01/08/2020 | B | 7680674550013 |
Limitation
No limitation is recorded on the SL for this preparation.
More preparations in this group
FAQ
Is Inhixa Multi covered by Swiss health insurance?
Yes. Inhixa Multi is on the FOPH Specialities List, so Swiss mandatory health insurance reimburses it within the authorised indication. You still pay the deductible and a co-payment of 10 per cent.
What does Inhixa Multi cost in Switzerland?
The public price is the maximum price set by the FOPH and for Inhixa Multi ranges from CHF 34.45 to CHF 34.45 per pack. The ex-factory price ranges from CHF 16.59 to CHF 16.59. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages